Susan Boklage

Suggest Changes
Learn More
e17548 Background: Docetaxel and paclitaxel are widely used in treating breast cancer (BC), and both have hematologic toxicity commonly managed by costly growth factors (GFs). However, the extent of(More)
  • 1